Aug 03 2017


Print this Post

Needleless dental anesthetic for upper anterior teeth

Getting one step closer to “No Needle Dentistry”. New nasal spray allow to do dental works for upper anterior teeth.

the U.S. Food and Drug Administration approved Kovanaze™ (St. Renatus, L.L.C.), a needleless, intranasally administered spray combination of the ester anesthetic tetracaine HCl plus the vasoconstrictor oxymetazoline HCl (6 mg/0.1 mg per 0.2 mL) for regional maxillary anesthesia.1-3 Kovanaze™ is indicated for regional pulpal anesthesia when performing a restorative procedure on teeth 4 through 13 and A through J in adults and children who weigh 40 kg (88 lbs) or more.1, 3 The drug is supplied as a prefilled, single-use sprayer that delivers 6 mg tetracaine HCl and 0.1 mg oxymetazoline HCl (equivalent to 5.27 mg tetracaine and 0.088 mg oxymetazoline) in each 0.2 mL spray.1

Kovanaze™ should be administered intranasally ipsilateral (on the same side) to the maxillary tooth on which the dental procedure will be performed. Recommended doses1 are as follows:

Adults (≥ 18 years old)

*2 sprays (0.2 mL per spray), 4 to 5 minutes apart
*1 additional spray (0.2 mL) if adequate anesthesia has not been achieved 10 minutes after the second spray

Children who weigh 40 kg or more

2 sprays (0.2 mL per spray), 4 to 5 minutes apart

Contraindications to Kovanaze™ include: known hypersensitivity to tetracaine, benzyl alcohol, other ester local anesthetics, p-aminobenzoic acid (PABA), oxymetazoline, or any other component of the product.1 The most common adverse reactions occurring in 10% or more of patients include rhinorrhea, nasal congestion, lacrimation increased, nasal discomfort, and oropharyngeal pain. Transient, asymptomatic elevations in systolic blood pressure (≥25 mm Hg from baseline) and diastolic blood pressures (≥15 mm Hg from baseline) have been reported.

Permanent link to this article: https://odentist.com/article/anesthesia/needleless-dental-anesthetic-for-upper-anterior-teeth/

Leave a Reply